An Open-Label Study of the Effects of Acetyl-L-Camitine on Cardiovascular Outcomes in Friedreich's Ataxia

Kelly L. Sullivan

An Open-Label Study of the Effects of Acetyl-L-Camitine on Cardiovascular Outcomes in Friedreich's Ataxia

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Other contribution › Other

Original language	American English
State	Published - 2012

Disciplines

Epidemiology
Public Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{89058e2216a0458b833916356b41f189,

title = "An Open-Label Study of the Effects of Acetyl-L-Camitine on Cardiovascular Outcomes in Friedreich's Ataxia",

author = "Sullivan, {Kelly L.}",

note = "Kelly L. Sullivan (Project Manager & Epidemiologist), {"}An Open-Label Study of the Effects of Acetyl-L-Camitine on Cardiovascular Outcomes in Friedreich's Ataxia,{"} Friedreich's Ataxia Research Alliance (Investigator Initiated). (2012-present).",

year = "2012",

language = "American English",

type = "Other",

}

TY - GEN

T1 - An Open-Label Study of the Effects of Acetyl-L-Camitine on Cardiovascular Outcomes in Friedreich's Ataxia

AU - Sullivan, Kelly L.

N1 - Kelly L. Sullivan (Project Manager & Epidemiologist), "An Open-Label Study of the Effects of Acetyl-L-Camitine on Cardiovascular Outcomes in Friedreich's Ataxia," Friedreich's Ataxia Research Alliance (Investigator Initiated). (2012-present).

PY - 2012

Y1 - 2012

UR - https://clinicaltrials.gov/show/NCT01921868

M3 - Other

ER -

An Open-Label Study of the Effects of Acetyl-L-Camitine on Cardiovascular Outcomes in Friedreich's Ataxia

Disciplines

UN SDGs

Other files and links

Cite this